TOP > 外国特許検索 > IMMUNOMODULATOR

IMMUNOMODULATOR

外国特許コード F180009374
整理番号 (S2016-0969-N0)
掲載日 2018年4月19日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2017JP029518
国際公開番号 WO 2018034318
国際出願日 平成29年8月17日(2017.8.17)
国際公開日 平成30年2月22日(2018.2.22)
優先権データ
  • 特願2016-160573 (2016.8.18) JP
発明の名称 (英語) IMMUNOMODULATOR
発明の概要(英語) The present invention provides a pharmaceutical composition used for the treatment or prevention of allergic diseases. More specifically, the present invention provides a pharmaceutical composition for the treatment or prevention of allergic diseases, that includes a substance that induces selective IgA class switching of B cells. A PKC activator can be used as the substance that induces selective IgA class switching of B cells. The composition including the substance that induces selective IgA class switching of B cells can be useful as a mucosal adjuvant.
特許請求の範囲(英語) [claim1]
1. 1 Bryostatin including, for use in the treatment of allergic disease or prevention of a pharmaceutical composition.
[claim2]
2. CD40 Free, a pharmaceutical composition according to claim 1.
[claim3]
3. 1 Bryostatin including, mucosal adjuvant composition.
[claim4]
4. 1 Bryostatin submucosally containing as an adjuvant, a vaccine composition mucosa.
[claim5]
5. B class switch selective IgA induced in a cell containing a substance, the selective IgA class switch bryostatin B induced in a cell in the materials 1, immunomodulatory agent.
[claim6]
6. 1 Bryostatin containing as an active ingredient, selective IgA B class switch composition for induced in a cell.
[claim7]
7. B class switch selective IgA crcyclodextrin induced in a cell, for use in the treatment of allergic disease or prevention of a pharmaceutical composition.
[claim8]
8. B class switch selective IgA substance induced in a cell, PKC activator, a pharmaceutical composition according to claim 7.
[claim9]
9. B class switch selective IgA substance induced in a cell, phorbol derivative or a macrolactone derivatives, claims 7 or 8 amonohydrate.
[claim10]
10. B class switch selective IgA india lactam V substance induced in a cell or a derivative thereof, PMA or a derivative thereof, or bryostatin or a derivative thereof, a pharmaceutical composition according to claims 7 or 8.
[claim11]
11. B class switch selective IgA induced in a cell of the substance, the following compounds selected from the group consisting of, claims 7 or 8 amonohydrate: phorbol 12-start milliQ 13-sapintoxin D,ROPA(Resiniferonol-9, 13, 14-orthophenyl acetate), prostratin (Phorbol 12-myristate 13-acetate) (PMA), acetate, neristatin, bryostatin 1, bryostatin 2, bryostatin 3, bryostatin 4, bryostatin 5, bryostatin 6, bryostatin 7, bryostatin 8, bryostatin 9, bryostatin 10, bryostatin 11, bryostatin 12, bryostatin 13, bryostatin 14, bryostatin 15, bryostatin 16, bryostatin 17, bryostatin 18, bryostatin 19, bryostatin 20, FR236924, (-) -india lactam V, PEP005, 12, 13 - - sn - -2 - myristoleyl (Phorbol 12,13-dibutyrate), SC-9,SC-10,1- phorbol jibuchirato substratepeptide arachidonyl glycerol (1-Oleoyl-2-acetyl-sn-glycerol), 1-O- hexadecyl - 2-O - - sn - glycerol (1-O-Hexadecyl-2-O-arachidonyl-sn-glycerol), 1,2- dioctanoyl - sn - glycerol (1,2-Dioctanoyl-sn-glycerol), PIP2, Resiniferatoxin, phorbol 12,13 - mezerein (Phorbol 12,13-Dihexanoate), dihexanoate (Mezerein), ingenol 3-A4(Lipoxin A4) lipoxin (Ingenol 3-Angelate), RHC-80267,DCP-LA, angerato, cyclopropanation polyunsaturated fatty acids, unsaturated fatty acids and one cyclopropanated, cyclopropanation polyunsaturated fatty alcohols, cyclopropanation monounsaturated fatty alcohol, cyclopropanation Polyunsaturated saturated fatty acid esters, cyclopropanation one unsaturated fatty acid esters, cyclopropanated ehthoxylated polyunsaturated fatty acids, unsaturated fatty acid ehthoxylated one cyclopropanation, cyclopropanation polyunsaturated fatty acid phosphate, cyclopropanation monounsaturated fatty acid phosphate, isoprenoids, octylphenyl lind lactam V, gunijimakurin, iriparidaru, ingenol, naphthalene sulfonamide, a fibroblast growth factor 18 (FGF-18), insulin growth factor, buriorogu, okadiac acid, diacylglycerol (DAG), Dimyristoyl (PS), DOG(1,2-dioctanoyl-sn-glycerol), OAG(1-oleoyl-2-acetyl-sn-glycerol), (2S,5S) -(E,E) -8-(5-(4-(trifluoromethyl) phenyl) -2,4 - pentadienone noil amino) benzolactam, oleic acid, 8S-HETE, clomiphene citrate, sodium oleate, phorbol 12,13 - diacetate, 12,13 - phorbol jidekanoeto, glycerol - sn - 1,2 - Dipalmitoyl, 1-- sn - glycerol Stearoyl -2 - method of claims, 12,13 - phorbol jihekisanoeto, resiniferonol ferro nord 9, 13, 14 - ortho-phenylacetate, C-8 Ceramide, 1,6 - bis (cyclohexyloxycarbonyl mino carbonyl amino) hexane, -2 - (+ / -) -L- acetyl glycerol oleoyl, zoledronic acid monohydrate, 12-deoxyholbo 13-angerato 20-acetate, 6--4 - (N - decylamino) hydroxymethyl indole, phorbol 12,13 - dibutyrate 4 α -, 1,2 - - sn - glycerol jihekisanoiru, tetrahydrate disodium zoledronic acid, arachidonic acid methyl ester, arachidonic acid and 10-Me-Aplog-1 -d8,De-OMe-DAT,Aplog-1.
[claim12]
12. For nasal administration, for use in oral administration, for administration, for use in administration to drop, or transdermal administration is for, according to any one of claims 7-11 of the pharmaceutical composition.
[claim13]
13. Allergic disease, atopic dermatitis, allergic rhinitis, allergic conjuctivitis, allergic gastroenteritis, bronchial asthma, pediatric asthma, food allergies, drug allergies, and is selected from the group consisting of urticaria, according to any one of claims 7-12 of the pharmaceutical composition.
[claim14]
14. B class switch selective IgA crcyclodextrin induced in a cell, mucosal adjuvant composition.
[claim15]
15. B class switch selective IgA substance induced in a cell, the activation agent PKC, according to claim 14 especailly adjuvant composition.
[claim16]
16. B class switch selective IgA substance induced in a cell, phorbol derivatives, macrolactone derivatives, claims 14 or 15 Mucoadherents of adjuvant composition.
[claim17]
17. B class switch selective IgA india lactam V substance induced in a cell or a derivative thereof, PMA or derivative thereof, or bryostatin or a derivative thereof, the composition of claims 14 or 15 Mucoadherents adjuvant.
[claim18]
18. B class switch selective IgA induced in a cell of the substance, the following compounds selected from the group consisting of, claims 14 or 15 Mucoadherents of adjuvant composition: phorbol 12-milli-start 13-sapintoxin D,ROPA(Resiniferonol-9, 13, 14-orthophenyl acetate), prostratin (Phorbol 12-myristate 13-acetate) (PMA), acetate, neristatin, bryostatin 1, bryostatin 2, bryostatin 3, bryostatin 4, bryostatin 5, bryostatin 6, bryostatin 7, bryostatin 8, bryostatin 9, bryostatin 10, bryostatin 11, bryostatin 12, bryostatin 13, bryostatin 14, bryostatin 15, bryostatin 16, bryostatin 17, bryostatin 18, bryostatin 19, bryostatin 20, FR236924, (-) -india lactam V, PEP005, 12, 13 - - sn - -2 - myristoleyl (Phorbol 12,13-dibutyrate), SC-9,SC-10,1- phorbol jibuchirato acetylations arachidonyl glycerol (1-Oleoyl-2-acetyl-sn-glycerol), 1-O- hexadecyl - 2-O - - sn - glycerol (1-O-Hexadecyl-2-O-arachidonyl-sn-glycerol), 1,2- dioctanoyl - sn - glycerol (1,2-Dioctanoyl-sn-glycerol), PIP2, Resiniferatoxin, phorbol 12,13 - mezerein (Phorbol 12,13-Dihexanoate), dihexanoate (Mezerein), ingenol 3-A4(Lipoxin A4) lipoxin (Ingenol 3-Angelate), RHC-80267,DCP-LA, angerato, cyclopropanation polyunsaturated fatty acids, unsaturated fatty acids and one cyclopropanated, cyclopropanation polyunsaturated fatty alcohols, cyclopropanation monounsaturated fatty alcohol, cyclopropanation Polyunsaturated saturated fatty acid esters, cyclopropanation one unsaturated fatty acid esters, cyclopropanated ehthoxylated polyunsaturated fatty acids, unsaturated fatty acid ehthoxylated one cyclopropanation, cyclopropanation polyunsaturated fatty acid phosphate, cyclopropanation monounsaturated fatty acid phosphate, isoprenoids, octylphenyl lind lactam V, gunijimakurin, iriparidaru, ingenol, naphthalene sulfonamide, a fibroblast growth factor 18 (FGF-18), insulin growth factor, buriorogu, okadiac acid, diacylglycerol (DAG), Dimyristoyl (PS), DOG(1,2-dioctanoyl-sn-glycerol), OAG(1-oleoyl-2-acetyl-sn-glycerol), (2S,5S) -(E,E) -8-(5-(4-(trifluoromethyl) phenyl) -2,4 - pentadienone noil amino) benzolactam, oleic acid, 8S-HETE, clomiphene citrate, sodium oleate, phorbol 12,13 - diacetate, 12,13 - phorbol jidekanoeto, glycerol - sn - 1,2 - Dipalmitoyl, 1-- sn - glycerol Stearoyl -2 - method of claims, 12,13 - phorbol jihekisanoeto, resiniferonol ferro nord 9, 13, 14 - ortho-phenylacetate, C-8 Ceramide, 1,6 - bis (cyclohexyloxycarbonyl mino carbonyl amino) hexane, -2 - (+ / -) -L- acetyl glycerol oleoyl, zoledronic acid monohydrate, 12-deoxyholbo 13-angerato 20-acetate, 6--4 - (N - decylamino) hydroxymethyl indole, phorbol 12,13 - dibutyrate 4 α -, 1,2 - - sn - glycerol jihekisanoiru, tetrahydrate disodium zoledronic acid, arachidonic acid methyl ester, arachidonic acid and 10-Me-Aplog-1 -d8,De-OMe-DAT,Aplog-1.
[claim19]
19. Any one of claims 14-18 Mucoadherents of containing the adjuvant, a vaccine composition mucosa.
[claim20]
20. B class switch selective IgA induced in a cell containing a substance, immunomodulatory agent.
[claim21]
21. B class switch selective IgA substance induced in a cell, the activation agent PKC, according to claim 20 immunomodulatory agent.
[claim22]
22. As an effective component containing an activator PKC, selective IgA B class switch composition for induced in a cell.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NARA INSTITUTE OF SCIENCE AND TECHNOLOGY
  • 発明者(英語)
  • SHINKURA REIKO
  • YAMAMOTO KOTA
国際特許分類(IPC)
指定国 (WO201834318)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記「問合せ先」までお問い合わせください。

PAGE TOP

close
close
close
close
close
close